NEW YORK (GenomeWeb) – MDxHealth reported today that its first quarter revenues rose 50 percent, thanks to a 55 percent increase in total test volumes.

For the three months ended March 31, the molecular diagnostics company said revenues rose to $9.7 million from $6.5 million in Q1 2017. Included in the total revenue for Q1 was a license fee payment of $500,000. Product revenues from the firm's ConfirmMDx and SelectMDx tests for prostate cancer amounted to $7.9 million and rose 60 percent from $4.9 million a year earlier.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.